WESTMINSTER, Colo., Nov. 16 /PRNewswire-FirstCall/ -- Allos Therapeutics,
Inc. (Nasdaq: ALTH) today announced that preliminary data from a Phase 1 study
evaluating the Company's novel antifolate PDX has been accepted for
presentation at the American Society of Hematology's 47th Annual Meeting, to
be held December 10 - 13 in Atlanta.
Owen O'Connor, M.D., Ph.D., Attending Physician, Department of Medicine,
Memorial Sloan-Kettering Cancer Center, is scheduled to report preliminary
observations from an on-going Phase 1 study of PDX in patients with relapsed
or refractory aggressive lymphoproliferative malignancies in a poster
presentation titled "Pralatrexate (10-Propargyl-10-Deazaaminopterin (PDX)), a
Novel Antifolate, Effects Durable Complete Remissions (CR) in Patients With a
Diversity of Drug Resistant T-Cell Lymphomas with Minimal Toxicity." on
Sunday, December 11.
A copy of the abstract is currently available on the American Society of
Hematology's web site, http://www.hematology.org.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company
focused on developing and commercializing innovative small molecule
therapeutics for the treatment of cancer. Our lead product candidate,
EFAPROXYN(TM) (efaproxiral), is a synthetic small molecule designed to
sensitize hypoxic, or oxygen-deprived, tumor tissue during radiation therapy.
EFAPROXYN is currently being evaluated as an adjunct to whole brain radiation
therapy in a pivotal Phase 3 trial in women with brain metastases originating
from breast cancer. Our other product candidates are: PDX (pralatrexate), a
small molecule chemotherapeutic agent (DHFR inhibitor) currently under
investigation as both a single agent and in combination therapy regimens in
patients with non-small cell lung cancer and Non-Hodgkin's lymphoma; and RH1,
a small molecule chemotherapeutic agent bioactivated by the enzyme
DT-diaphorase currently under evaluation in patients with advanced solid
tumors. For more information, please visit the Company's web site at:
http://www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that
involve significant risks and uncertainties, including those to be discussed
in the presentation and others that can be found in the "Risk Factors" section
of the Company's Form 10-K for the year ended December 31, 2004 and in the
Company's periodic reports on Form 10-Q and Form 8-K. The Company does not
undertake any obligation to update any forward-looking statements contained in
the anticipated presentation as a result of new information, future events or
otherwise. The Company cautions investors not to place undue reliance on the
forward-looking statements contained in the presentation. No forward-looking
statement can be guaranteed and actual events and results may differ
materially from those projected.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Jennifer Neiman, Manager, Corporate
Communications, of Allos Therapeutics, +1-720-540-5227,
jneiman@allos.com
|
